These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 32998736

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC, Lip GYH.
    Cardiovasc Diabetol; 2022 Jun 28; 21(1):118. PubMed ID: 35765074
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X, Zhang N, Lu L, Gao T, Chou OHI, Wong WT, Chang C, Wai AKC, Lip GYH, Zhang Q, Tse G, Liu T, Zhou J.
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb 23; 10(2):103-117. PubMed ID: 37962962
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL, Halvorson AE, Hackstadt AJ, Hung AM, Greevy R, Grijalva CG, Elasy TA, Roumie CL.
    Ann Intern Med; 2023 Jun 23; 176(6):751-760. PubMed ID: 37155984
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N.
    Circulation; 2018 Apr 03; 137(14):1450-1459. PubMed ID: 29133607
    [Abstract] [Full Text] [Related]

  • 12. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
    Chen TH, Li YR, Chen SW, Lin YS, Sun CC, Chen DY, Mao CT, Wu M, Chang CH, Chu PH, Wu VC.
    Cardiovasc Diabetol; 2020 Nov 09; 19(1):189. PubMed ID: 33167990
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.
    Lin YH, Lin CH, Lin YC, Huang YY, Tai AS, Fu SC, Lin SH.
    Endocr Pract; 2024 May 09; 30(5):424-430. PubMed ID: 38325629
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
    Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J.
    Cardiovasc Diabetol; 2021 Jul 09; 20(1):139. PubMed ID: 34243779
    [Abstract] [Full Text] [Related]

  • 16. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI, Ning J, Chan RNC, Chung CT, Huang H, Ng K, Dee EC, Lee S, Kaewdech A, Chow AKM, Man NK, Liu T, Jing F, Cheung BMY, Tse G, Zhou J.
    J Natl Compr Canc Netw; 2024 Jun 09; 22(2 D):. PubMed ID: 38862004
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
    Shikamura M, Takayama A, Takeuchi M, Kawakami K.
    Diabetes Obes Metab; 2024 Aug 09; 26(8):3099-3109. PubMed ID: 38708591
    [Abstract] [Full Text] [Related]

  • 20. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
    Chung CT, Lakhani I, Chou OHI, Lee TTL, Dee EC, Ng K, Wong WT, Liu T, Lee S, Zhang Q, Cheung BMY, Tse G, Zhou J.
    Cancer Med; 2023 Jun 09; 12(11):12299-12315. PubMed ID: 37148547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.